AbbVie's Outlook for the Next Five Years
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Significant Sales Growth: In the first nine months of 2025, combined sales of Skyrizi and Rinvoq reached approximately $15 billion, accounting for nearly 45% of AbbVie's total revenue, highlighting the critical role these drugs will play in the company's future finances.
- Strong Market Forecast: Analysts predict that by 2030, sales for Skyrizi and Rinvoq will reach at least $32 billion, further solidifying AbbVie's market position in immunology.
- Huge New Drug Potential: AbbVie's cancer therapy Elahere and Parkinson's drug Vyalev are expected to become new blockbusters within the next five years, potentially driving overall revenue growth for the company.
- Ongoing Dividend Growth: AbbVie has increased its dividend for 54 consecutive years and is expected to continue this trend, further boosting investor confidence and enhancing the company's value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 220.430
Low
218.00
Averages
253.26
High
289.00
Current: 220.430
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie's Outlook for the Next Five Years
- Significant Sales Growth: In the first nine months of 2025, combined sales of Skyrizi and Rinvoq reached approximately $15 billion, accounting for nearly 45% of AbbVie's total revenue, highlighting the critical role these drugs will play in the company's future finances.
- Strong Market Forecast: Analysts predict that by 2030, sales for Skyrizi and Rinvoq will reach at least $32 billion, further solidifying AbbVie's market position in immunology.
- Huge New Drug Potential: AbbVie's cancer therapy Elahere and Parkinson's drug Vyalev are expected to become new blockbusters within the next five years, potentially driving overall revenue growth for the company.
- Ongoing Dividend Growth: AbbVie has increased its dividend for 54 consecutive years and is expected to continue this trend, further boosting investor confidence and enhancing the company's value.
Continue Reading
Key Highlights to Monitor This Week: Jobs Report, Amazon, Disney, Alphabet, Palantir, and More
Market Volatility: Last week saw increased volatility in equities, with the S&P 500 ending slightly up and the Nasdaq Composite slightly down after a steady interest rate announcement by the Federal Open Market Committee.
Microsoft's Earnings Impact: Microsoft experienced a significant drop of 10% in its stock value, resulting in a loss of $357 billion in market capitalization following a disappointing earnings report.
Silver Market Collapse: The silver market faced a dramatic decline, falling 31% in a single day, attributed to the nomination of hawkish Kevin Warsh as the next Fed Chair and a prior 50% increase in value this year.
Overall Economic Sentiment: The combination of these events reflects a turbulent economic sentiment, with investors reacting to both corporate earnings and shifts in monetary policy.
Continue Reading